Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00113386 · ClinicalTrials.gov registry record · Phase 3
Cisplatin and Docetaxel With or Without Radiation Therapy in Treating Patients Who Are Undergoing Surgery for Newly Diagnosed Stage III Non-Small Cell Lung Cancer
A Phase 3 study, sponsored by Radiation Therapy Oncology Group.
- Terminated
- Registry status
- Phase 3
- Development phase
- 19
- Enrollment target
NCT00113386 is a Phase 3 study that was terminated before completion, run by Radiation Therapy Oncology Group. The registered enrollment target is 19 participants.
The verdict
NCT00113386, a Phase 3 study, was terminated before completion, sponsored by Radiation Therapy Oncology Group.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 19 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy, such as cisplatin and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Cisplatin and docetaxel may make tumor cells more sensitive to radiation therapy. Giving more than one drug (combination chemotherapy) together with radiation therapy before surgery may shrink the tumor so it can be removed. Giving chemotherapy after surgery may kill any tumor cells that remain after surgery. It is not yet known whether giving cisplatin and docetaxel together with radiation therapy is more effective than giving cisplatin together with docetaxel in treating non-small cell lung cancer. PURPOSE: This randomized phase III trial is studying cisplatin, docetaxel, and radiation therapy to see how well they work compared to cisplatin and docetaxel in treating patients who are undergoing surgery for newly diagnosed stage III non-small cell lung cancer.
Interventions
- DRUG cisplatin
- DRUG docetaxel
- PROCEDURE adjuvant therapy
- BIOLOGICAL filgrastim
- BIOLOGICAL pegfilgrastim
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2005-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00113386
The ClinicalTrials.gov registry entry for NCT00113386 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Radiation Therapy Oncology Group, which has 144 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which cisplatin is the first listed.
NCT00113386 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00113386 about?
NCT00113386 is a clinical study titled "Cisplatin and Docetaxel With or Without Radiation Therapy in Treating Patients Who Are Undergoing Surgery for Newly Diagnosed Stage III Non-Small Cell Lung Cancer". RATIONALE: Drugs used in chemotherapy, such as cisplatin and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Cisplatin and docetaxel may make tumor cells...
What is the current status of trial NCT00113386?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 19 participants. The study started on 2005-04.
What interventions are being tested in trial NCT00113386?
The interventions under investigation include: cisplatin (DRUG), docetaxel (DRUG), adjuvant therapy (PROCEDURE), filgrastim (BIOLOGICAL), pegfilgrastim (BIOLOGICAL).
Who is sponsoring clinical trial NCT00113386?
This trial is sponsored by Radiation Therapy Oncology Group, which has 144 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.